- Home
- AAMI vs RCUS Comparison
AAMI vs RCUS Comparison
Compare AAMI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- RCUS
- Stock Information
- Founded
- AAMI 1980
- RCUS 2015
- Country
- AAMI United States
- RCUS United States
- Employees
- AAMI N/A
- RCUS N/A
- Industry
- AAMI Investment Managers
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- AAMI Finance
- RCUS Health Care
- Exchange
- AAMI Nasdaq
- RCUS Nasdaq
- Market Cap
- AAMI 1.1B
- RCUS 906.4M
- IPO Year
- AAMI N/A
- RCUS 2018
- Fundamental
- Price
- AAMI $35.80
- RCUS $8.36
- Analyst Decision
- AAMI Hold
- RCUS Buy
- Analyst Count
- AAMI 2
- RCUS 10
- Target Price
- AAMI $27.00
- RCUS $23.75
- AVG Volume (30 Days)
- AAMI 250.6K
- RCUS 1.2M
- Earning Date
- AAMI 07-31-2025
- RCUS 08-07-2025
- Dividend Yield
- AAMI 0.11%
- RCUS N/A
- EPS Growth
- AAMI 46.05
- RCUS N/A
- EPS
- AAMI 2.40
- RCUS N/A
- Revenue
- AAMI $519,799,999.00
- RCUS $141,000,000.00
- Revenue This Year
- AAMI $5.28
- RCUS N/A
- Revenue Next Year
- AAMI $6.24
- RCUS $28.73
- P/E Ratio
- AAMI $14.68
- RCUS N/A
- Revenue Growth
- AAMI 18.00
- RCUS N/A
- 52 Week Low
- AAMI $21.49
- RCUS $6.50
- 52 Week High
- AAMI $35.99
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- AAMI N/A
- RCUS 39.01
- Support Level
- AAMI N/A
- RCUS $7.91
- Resistance Level
- AAMI N/A
- RCUS $8.87
- Average True Range (ATR)
- AAMI 0.00
- RCUS 0.48
- MACD
- AAMI 0.00
- RCUS -0.14
- Stochastic Oscillator
- AAMI 0.00
- RCUS 8.24
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.